What ACI is and whether you might qualify

If your consultant has mentioned ACI, the first question worth answering is a practical one: is this a procedure that could genuinely restore your knee, or is it simply managing symptoms?

ACI — autologous chondrocyte implantation — is a restorative cell therapy. It replaces a focal area of damaged articular cartilage with chondrocytes grown from your own knee cells, aiming to regenerate load-bearing tissue rather than mask the problem. The goal is joint preservation: delaying or avoiding knee replacement in an otherwise still-functional knee.

The procedure targets focal defects, not the diffuse cartilage loss seen in established osteoarthritis. Defect size is the primary sorting gate. Smaller lesions under 2 cm² are typically addressed by single-stage options such as AMIC, OATS, or a ChondroFiller injection. ACI sits in the 2–10 cm² range, where cell-based restoration has the strongest evidence.

The typical candidate is an active adult under 50 with a symptomatic focal defect confirmed on MRI, minimal or no osteoarthritic change, and no prior cartilage repair surgery on the same knee — criteria that align directly with the four NHS eligibility gates set out under NICE TA477 (October 2017).

NHS funding: the four eligibility gates

Each gate in the TA477 framework exists for a clinical reason, not administrative convenience.

1. Defect larger than 2 cm² — smaller lesions carry a reasonable chance of repair through less resource-intensive single-stage procedures; NHS cell therapy is reserved for the size range where those options have weaker long-term evidence.

2. No prior cartilage repair surgery on the same knee — previous marrow-stimulation procedures such as microfracture can damage the subchondral bone plate and alter local biology, reducing the likelihood of ACI achieving durable integration.

3. Minimal or no osteoarthritis, confirmed by a validated clinical measure — ACI restores focal defects within an otherwise viable joint environment. Established osteoarthritic change shifts the appropriate pathway toward joint preservation or replacement rather than cell-based restoration.

4. Treatment at a designated NHS tertiary centre — cell manufacture and implantation require specialist laboratory infrastructure and surgical volume that only a small number of hospitals in England maintain.

TA508 (March 2018) extended the same framework to cover chondrosphere-based ACI (Spherox), a spheroid cell product, under identical eligibility criteria.

Failing any single gate removes NHS commissioning — including patients whose sole disqualifier is a previous microfracture at the same site. For those patients, privately funded ACI, STACi, or AMIC may become the relevant options, though neither STACi nor standalone AMIC falls under any current NICE technology appraisal. That narrowness also has a stark geographic dimension for Lincolnshire patients.

The referral journey for Lincolnshire patients

Geography is the defining practical constraint for any Lincolnshire patient who qualifies. NHS ACI is performed at three principal centres — RJAH in Oswestry, the Royal National Orthopaedic Hospital (RNOH) in Stanmore, and University Hospital Southampton — none of which operates within the county.

RJAH carries the longest institutional history: the procedure was developed there over more than two decades of clinical trials under Professor James Richardson before NICE approval in October 2017. Today the programme is led by Mr Pete Gallacher, Mr Paul Jermin, and Mr Andrew Barnett, with cell manufacturing handled on-site through the Oscell facility in partnership with Keele University.

Reaching that expertise involves three sequential steps before treatment begins: a GP referral to a local Lincolnshire orthopaedic specialist, clinical assessment and onward tertiary referral from that specialist, then a booking at the chosen tertiary centre. Both surgical stages — the initial biopsy and, several weeks later, the implantation — require separate journeys out of county. That multi-step chain is unavoidable under the TA477 framework; patients who want an honest waiting-time estimate for their specific situation should ask their GP or local orthopaedic team at the point of referral, as NHS pathway timings vary between ICB commissioners and individual centre capacity.

For patients who want to move more quickly through the diagnostic and planning phase, private assessment removes the queueing structure at the front end. Lincolnshire Knee, part of the MSK Doctors group, sees patients without a referral at Sleaford NG34 and Grantham NG31; on-site onMRI™ AI-driven MRI analysis can characterise defect size and depth before any referral decision is made, giving patients and their clinician a clearer picture of whether the NHS ACI pathway, a private alternative, or a single-stage procedure is the appropriate next step.

Book an assessment at lincolnshireknee.co.uk.

Private ACI costs and what drives the price

Two factors drive the cost of private ACI far above most knee procedures: the two-stage surgical structure, and the specialist cell-culture laboratory sitting between those stages.

For the current matrix-assisted variant (MACI), private pricing in the UK runs at approximately £25,000–£35,000 all-in, based on London Cartilage Clinic April 2026 data. Of that total, the laboratory cell-culture phase alone accounts for £10,000–£17,000 — the cost of multiplying a small cartilage biopsy into enough viable cells for implantation. Add two sets of theatre fees, surgeon and anaesthetist charges, and post-operative physiotherapy (often billed separately at £500–£1,500), and the cumulative figure becomes clear. First-generation ACI using a periosteal patch is typically slightly lower, at £15,000–£28,000, with the range reflecting surgical complexity and centre.

STACi, a single-stage scaffold-based alternative, is priced at approximately £28,000 all-inclusive privately. Eliminating the inter-stage laboratory wait removes one logistical barrier, but STACi carries emerging rather than long-term outcomes data and is not currently NHS-commissioned under any NICE technology appraisal.

For patients who do not meet ACI eligibility — particularly those with smaller focal defects below 2 cm² or mild osteoarthritic change — a ChondroFiller injection as an ultrasound-guided outpatient injectable collagen scaffold treatment starts from approximately £3,000: a structurally different cost profile suited to a different point on the defect-severity spectrum.

Private initial consultation with a knee cartilage specialist in Lincolnshire is approximately £200–£250; patients should confirm the current figure directly with the clinic when enquiring.

Two stages, one year: what the ACI timeline involves

Planning around ACI means thinking in months, not weeks — and for patients in physically demanding work, that calendar has real consequences.

Stage 1 is a short keyhole operation: the surgeon takes a small sample of healthy cartilage from a non-weight-bearing zone of the knee. That biopsy then travels to a specialist cell laboratory, where the harvested chondrocytes multiply to at least twenty times their original number over roughly three to six weeks, either in suspension (first-generation ACI) or seeded onto a collagen membrane (MACI). Once enough viable cells exist, Stage 2 — the implantation — is booked. For Lincolnshire patients, both operations mean a separate out-of-county journey, so travel and accommodation logistics need to be factored in twice.

After Stage 2, the recovery follows a staged protocol. Crutches and protected weight-bearing continue for six to eight weeks; low-impact exercise typically becomes possible from around four to six months; running and higher-impact activity from nine to twelve months; and the cartilage graft reaches full biological maturation at approximately eighteen months. That final figure is not a complication — it reflects proper integration of new tissue into living bone and adjacent cartilage.

For patients in construction, agriculture, or other physically demanding occupations common across Lincolnshire, a phased return-to-work plan is essential. Access to a physiotherapist close to home for the post-operative programme — rather than travelling to the treating centre for every session — is a practical priority worth arranging before Stage 1 takes place.

How durable are the results: 10-year outcome evidence

Ten-year follow-up data from two independent MACI cohorts offers a reasonably clear picture of what durable success looks like. In a systematic review of 168 patients assessed at a minimum of ten years, 92% reported satisfaction with pain relief, MRI graft integrity scores remained stable from two to ten years, and only 7.4% had progressed to total knee arthroplasty — a conversion rate that validates ACI as a joint-preserving strategy rather than a temporary fix.

A network meta-analysis of 19 randomised controlled trials found no statistically significant difference in patient-reported outcomes between ACI, AMIC, and other cartilage repair techniques at short, intermediate, or long-term follow-up, suggesting the clinical superiority gap between approaches is narrowing for mid-range focal defects. Outcomes remain most reliable in younger, active patients with isolated lesions and no history of prior marrow-stimulation procedures; defects exceeding 4.5 cm² and increasing patient age are both associated with higher reoperation risk.

One nuance carries particular relevance for Lincolnshire. A 2025 UK study of 391 ACI patients found that those from more deprived areas — specifically neighbourhoods with high unemployment — had significantly lower Lysholm scores at one year, even after adjusting for age, sex, and BMI. The practical implication is straightforward: securing local physiotherapy access before Stage 1 takes place, rather than leaving post-operative rehabilitation to chance, may meaningfully improve outcomes for patients in those communities.

For anyone wanting to understand whether ACI eligibility applies to their situation, Lincolnshire Knee accepts assessments without a GP referral — lincolnshireknee.co.uk.

1. [1] Minimum 10-Year Outcomes of Matrix-Induced Autologous Chondrocyte Implantation in the Knee. (2024). https://doi.org/10.1177/03635465231205309 https://doi.org/10.1177/03635465231205309
2. [2] 10-Year Prospective Clinical and Radiological Evaluation After MACI and Comparison of Tibiofemoral and Patellofemoral Graft Outcomes. (2024). https://doi.org/10.1177/03635465241227969 https://doi.org/10.1177/03635465241227969
3. [3] Socioeconomic Area Deprivation is Related to Poorer Patient-Reported Outcomes Following ACI. (2025). https://doi.org/10.1177/19476035251360503 https://doi.org/10.1177/19476035251360503